BE2020C004I2 - - Google Patents

Info

Publication number
BE2020C004I2
BE2020C004I2 BE2020C004C BE2020C004C BE2020C004I2 BE 2020C004 I2 BE2020C004 I2 BE 2020C004I2 BE 2020C004 C BE2020C004 C BE 2020C004C BE 2020C004 C BE2020C004 C BE 2020C004C BE 2020C004 I2 BE2020C004 I2 BE 2020C004I2
Authority
BE
Belgium
Application number
BE2020C004C
Other languages
Dutch (nl)
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37085728&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2020C004(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of BE2020C004I2 publication Critical patent/BE2020C004I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BE2020C004C 2005-06-08 2020-05-07 BE2020C004I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68863805P 2005-06-08 2005-06-08
PCT/US2006/022407 WO2006133393A1 (fr) 2005-06-08 2006-06-07 Traitement de troubles du cycle sommeil-eveil

Publications (1)

Publication Number Publication Date
BE2020C004I2 true BE2020C004I2 (fr) 2026-01-06

Family

ID=37085728

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2020C004C BE2020C004I2 (fr) 2005-06-08 2020-05-07

Country Status (17)

Country Link
US (8) US8440715B2 (fr)
EP (1) EP1890684B1 (fr)
JP (1) JP5024635B2 (fr)
KR (1) KR101335941B1 (fr)
CN (1) CN101217949B (fr)
AU (1) AU2006254899B2 (fr)
BE (1) BE2020C004I2 (fr)
BR (1) BRPI0613697A2 (fr)
CA (1) CA2611713C (fr)
DK (1) DK1890684T3 (fr)
ES (1) ES2435403T3 (fr)
FR (1) FR20C1014I2 (fr)
NL (1) NL301037I2 (fr)
PL (1) PL1890684T3 (fr)
RU (1) RU2417077C2 (fr)
TW (2) TWI419681B (fr)
WO (1) WO2006133393A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006254899B2 (en) 2005-06-08 2011-11-24 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
DE602006012670D1 (de) * 2005-06-22 2010-04-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
RU2567801C2 (ru) 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
US8232315B2 (en) * 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
WO2011055944A2 (fr) * 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Procédés pour traiter un syndrome de fibromyalgie
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US8623913B2 (en) * 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy
PL3021838T3 (pl) * 2013-07-18 2021-03-08 Jazz Pharmaceuticals Ireland Limited Leczenie otyłości
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI655179B (zh) 2014-02-28 2019-04-01 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
WO2016061488A1 (fr) 2014-10-17 2016-04-21 Concert Pharmaceuticals, Inc. Inhibiteurs de réabsorption d'amines
JP6466792B2 (ja) * 2015-07-03 2019-02-06 エスケー バイオファーマスティカルズ カンパニー リミテッド 注意欠陥／多動性障害（ａｄｈｄ）の治療方法
TWI637765B (zh) * 2016-05-10 2018-10-11 台灣共振波研發股份有限公司 Soothing device for attention deficit hyperactivity disorder
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
CN120574152A (zh) 2016-09-06 2025-09-02 爱尔兰贾兹制药有限公司 (r)-2-氨基-3-苯丙基氨基甲酸酯盐酸盐的溶剂化物形式的晶体、其制备方法、组合物及用途
MY202185A (en) 2016-10-06 2024-04-15 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol compounds and uses therof
EP3630072A4 (fr) 2017-06-02 2021-03-10 Jazz Pharmaceuticals Ireland Limited Procédés et compositions pour le traitement d'une somnolence excessive
MX2020001146A (es) 2017-07-31 2020-08-20 Jazz Pharmaceuticals Ireland Ltd Analogos de carbamoil fenilalaninol y usos de los mismos.
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11033214B1 (en) * 2020-05-19 2021-06-15 United Arab Emirates University Wearable eye tracking system
KR102390194B1 (ko) 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
EP4615426A1 (fr) * 2022-11-07 2025-09-17 Axsome Therapeutics Compositions et méthodes de traitement de l'insomnie
EP4626417A1 (fr) * 2022-11-30 2025-10-08 Axsome Therapeutics Méthodes et compositions d'amélioration de performances de conduite
WO2025006965A1 (fr) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Procédés d'administration de solriamfétol à des femmes en lactation
WO2025165760A1 (fr) * 2024-01-29 2025-08-07 Axsome Therapeutics, Inc. Phénylalkylamino-carbamates destinés à être utilisés dans le traitement du trouble déficit de l'attention/hyperactivité

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2939660A1 (de) 1979-09-29 1981-04-16 Basf Ag, 6700 Ludwigshafen Neue carbamate, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
NZ314570A (en) 1993-06-10 2000-11-24 Lilly Co Eli Treatment of emesis using tetrahydrobenz[cd]indole-6-carboxamides
KR100197892B1 (ko) 1994-09-09 1999-06-15 남창우 신규한 페닐알킬아미노 카바메이트 화합물과 그의 제조방법
KR0173862B1 (ko) 1995-02-11 1999-04-01 조규향 O-카바모일-(d)-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
US5756817C1 (en) * 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
DE69618663T2 (de) * 1996-10-10 2002-08-14 Sk Corp., Seoul/Soul O-carbamoyl-phenylalaninol-zusammensetzungen und ihre pharmazeutisch anwendbaren salzen
WO1998017636A1 (fr) 1996-10-22 1998-04-30 Ortho Pharmaceutical Corporation Derives de phenylalaninol pour le traitement de troubles du systeme nerveux central
CZ20032300A3 (cs) 2001-02-27 2005-01-12 Ortho-Mcneil Pharmaceutical, Inc. Léčivo pro prevenci nebo léčbu bipolárních chorob
CZ20032311A3 (cs) 2001-02-27 2005-02-16 Ortho-Mcneil Pharmaceutical, Inc. Karbamátová sloučenina a léčivo pro prevenci a léčení úzkosti
DE60221670T2 (de) 2001-02-27 2008-04-30 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
KR20070083826A (ko) 2004-10-28 2007-08-24 에스케이 주식회사 우울증을 위한 부가 요법
AU2006254899B2 (en) 2005-06-08 2011-11-24 Sk Biopharmaceuticals Co., Ltd. Treatment of sleep-wake disorders
DE602006012670D1 (de) 2005-06-22 2010-04-15 Sk Holdings Co Ltd Behandlung der sexuellen dysfunktion
CA2616721C (fr) 2005-07-26 2014-01-21 Janssen Pharmaceutica N.V. Procedes pour traiter des troubles lies a des substances
CA2673487A1 (fr) 2006-10-13 2008-04-24 Janssen Pharmaceutica Nv Compositions de phenylalkylaminocarbamate
RU2567801C2 (ru) 2009-06-22 2015-11-10 Ск Биофармасъютиклс Ко., Лтд. Способы лечения и профилактики усталости
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
WO2011055944A2 (fr) 2009-11-06 2011-05-12 Sk Holdings Co., Ltd. Procédés pour traiter un syndrome de fibromyalgie
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
KR102005483B1 (ko) 2012-10-19 2019-07-31 삼성디스플레이 주식회사 박막 트랜지스터 기판 및 그의 수리 방법
US9359290B2 (en) * 2013-03-13 2016-06-07 Jazz Pharmaceuticals International Iii Limited Treatment of cataplexy

Also Published As

Publication number Publication date
US20240239740A1 (en) 2024-07-18
JP5024635B2 (ja) 2012-09-12
CN101217949A (zh) 2008-07-09
US11753368B2 (en) 2023-09-12
BRPI0613697A2 (pt) 2011-01-25
EP1890684A1 (fr) 2008-02-27
NL301037I2 (nl) 2020-05-12
PL1890684T3 (pl) 2014-05-30
US8877806B2 (en) 2014-11-04
US8440715B2 (en) 2013-05-14
CA2611713C (fr) 2013-10-01
US20170158622A1 (en) 2017-06-08
US10351517B2 (en) 2019-07-16
EP1890684B1 (fr) 2013-08-14
US20140350098A1 (en) 2014-11-27
US12209059B2 (en) 2025-01-28
KR20080035565A (ko) 2008-04-23
AU2006254899B2 (en) 2011-11-24
TW200716084A (en) 2007-05-01
JP2008545795A (ja) 2008-12-18
CA2611713A1 (fr) 2006-12-14
KR101335941B1 (ko) 2013-12-04
US20210078943A1 (en) 2021-03-18
US9604917B2 (en) 2017-03-28
ES2435403T3 (es) 2013-12-19
CN101217949B (zh) 2012-10-17
WO2006133393A1 (fr) 2006-12-14
FR20C1014I1 (fr) 2020-06-12
RU2417077C2 (ru) 2011-04-27
AU2006254899A1 (en) 2006-12-14
US20250109099A1 (en) 2025-04-03
TWI419681B (zh) 2013-12-21
NL301037I1 (fr) 2020-04-01
US20090312416A1 (en) 2009-12-17
RU2008100019A (ru) 2009-07-20
FR20C1014I2 (fr) 2021-04-23
US20130137764A1 (en) 2013-05-30
US20190367448A1 (en) 2019-12-05
DK1890684T3 (da) 2013-10-14
TW201328689A (zh) 2013-07-16

Similar Documents

Publication Publication Date Title
BE2025C533I2 (fr)
BE2024C510I2 (fr)
BE2023C529I2 (fr)
BE2021C552I2 (fr)
BE2021C557I2 (fr)
BE2021C531I2 (fr)
BE2021C519I2 (fr)
BE2020C531I2 (fr)
BE2020C511I2 (fr)
BE2020C508I2 (fr)
FR20C1014I1 (fr)
BE2019C521I2 (fr)
BE2019C503I2 (fr)
BE2018C037I2 (fr)
BE2018C035I2 (fr)
BE2018C019I2 (fr)
BE2019C533I2 (fr)
BE2017C007I2 (fr)
BE2018C028I2 (fr)
BE2016C045I2 (fr)
BE2016C022I2 (fr)
BE2014C012I2 (fr)
BE2014C057I2 (fr)
BE2013C074I2 (fr)
BE2012C042I2 (fr)